Tiigi and Välja facilities form a fully integrated CDMO platform supporting route design, process optimisation, clinical supply, and commercial API manufacturing.
R&D, Analytics and Small-Scale manufacturing
Tiigi tn 61b, 50410 Tartu, Estonia
Located at Tartu Biotechnology Park (Tiigi tn 61b, Tartu, Estonia), the Tiigi facility serves as TBD Pharmatech’s integrated hub for small-molecule API development, analytical quality control, and early-phase GMP manufacturing.
The site comprises approximately 1,000 m² of GMP-certified laboratories and production areas, supporting seamless progression from route design and process optimisation through scale-up and clinical batch supply. Eight dedicated cGMP production rooms enable flexible batch sizes from milligram quantities to 150 L scale.
Tiigi is designed to translate laboratory chemistry into scalable, manufacturing-ready processes. Capabilities include:
Jacketed glass and glass-lined reactors up to 150 L
High-pressure systems for reaction screening and catalytic transformations
Wide-range temperature control (sub-zero to elevated temperatures)
Crystallisation and isolation development
Preparative chromatography (Flash, Prep-HPLC) for development support
Vacuum-assisted Nutsche filtration and centrifugation
Controlled solvent removal and vacuum drying systems
Particle-size reduction and final API finishing
On-site analytical laboratories provide comprehensive method development, validation, stability studies, and GMP release testing using advanced chromatographic and physicochemical instrumentation.
By integrating R&D, analytical sciences, and GMP manufacturing under one roof, the Tiigi site eliminates handover gaps, accelerates tech transfer, and establishes a robust foundation for progression into commercial-scale production at our Välja facility.
Commercial-Scale EU-GMP Manufacturing
Välja 4a, 61709, Soinaste, Tartu county, Estonia
Located in Tartu County, Estonia, the Välja facility is TBD Pharmatech’s dedicated commercial manufacturing site. Fully EU-GMP certified, the plant provides over 3,000 m² of production space designed for reliable, scalable small-molecule API manufacturing within the European Union.
Purpose-built for niche-to-mid-volume production, Välja strengthens EU-based supply security while offering capacity for future expansion.
The facility supports flexible and robust API production through:
Glass-lined reactor systems from pilot scale up to 1,000 L
Controlled temperature operations across a wide operating range
High-pressure and catalytic reaction capability where required
Integrated vacuum infrastructure for solvent management
Designed to prioritize crystallisation-based isolation and scalable purification strategies, Välja integrates:
Stainless steel and glass-lined Nutsche filtration systems
Production-scale centrifugation
Vacuum and convection drying technologies
Controlled final API processing and packaging environments
The site houses ten dedicated GMP production suites engineered for segregated material and personnel flows, ensuring contamination-controlled operations and consistent batch quality.
Välja provides a secure EU manufacturing base for multi-kilogram to tonne-scale annual demand, whether scaling a process developed at our Tiigi site or transferring an established manufacturing route under full GMP control.
API CDMO that delivers a tailored range of fine chemical development and manufacturing solutions to pharmaceutical and biotech companies.
